In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.
In patients with low-grade upper tract urothelial carcinoma, treatment with intracavitary UGN-101 (mitomycin gel; Jelmyto) resulted in a high rate of disease eradication that was found to be durable in a majority of patients, results of the OLYMPUS Trial showed. In this interview, senior author Seth P. Lerner, MD, discusses the study’s efficacy and tolerability data and where this therapy fits into the current treatment paradigm. Lerner was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD. Disclosure: The OLYMPUS Trial was funded by UroGen Pharma.
Dr. Syan recaps AUA 2024 sessions on urodynamics, PTNS devices
May 24th 2024Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.